Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$5.02 -0.6%	$4.98	$1.62 ▼ $7.27	$450.16M	-0.59	1.19 million shs	822,649 shs
BHVN Biohaven	$14.44 -0.2%	$17.82	$13.87 ▼ $55.70	$1.48B	0.95	1.28 million shs	1.38 million shs
DVAX Dynavax Technologies	$9.77 -2.2%	$10.26	$9.22 ▼ $14.63	$1.20B	1.07	2.17 million shs	1.32 million shs
FGEN FibroGen	$5.40 -6.1%	$7.52	$4.50 ▼ $38.25	$23.24M	0.83	79,385 shs	49,329 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-0.59%	-7.72%	-5.46%	+32.80%	+182.02%
BHVN Biohaven	-0.48%	-4.99%	-7.88%	-51.56%	-56.99%
DVAX Dynavax Technologies	-2.20%	-3.93%	-0.31%	-30.11%	-14.52%
FGEN FibroGen	-6.09%	-18.83%	-34.55%	-36.95%	-80.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.6184 of 5 stars	4.6	3.0	0.0	1.3	3.3	0.6
BHVN Biohaven	3.1583 of 5 stars	4.5	1.0	0.0	2.2	2.5	0.6
DVAX Dynavax Technologies	4.2343 of 5 stars	3.3	1.0	4.7	2.5	1.7	1.9
FGEN FibroGen	4.4019 of 5 stars	3.3	5.0	4.7	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.10	Buy	$10.14	102.05% Upside
BHVN Biohaven	3.07	Buy	$58.46	305.00% Upside
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.00	145.65% Upside
FGEN FibroGen	2.50	Moderate Buy	$250.00	4,529.63% Upside

Current Analyst Ratings Breakdown

Latest FGEN, BHVN, AMLX, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/19/2025	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/13/2025	FGEN FibroGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $250.00
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/7/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $31.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	5.12	N/A	N/A	$2.40 per share	2.09
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
DVAX Dynavax Technologies	$277.25M	4.23	$0.15 per share	63.09	$4.54 per share	2.15
FGEN FibroGen	$29.62M	0.74	N/A	N/A	($50.89) per share	-0.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
DVAX Dynavax Technologies	$27.31M	-$0.52	N/A	19.94	N/A	-20.39%	3.59%	2.20%	8/5/2025 (Estimated)
FGEN FibroGen	-$47.58M	-$2.50	N/A	N/A	N/A	-9.73%	N/A	-24.77%	8/5/2025 (Estimated)

Latest FGEN, BHVN, AMLX, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/12/2025	Q1 2025	FGEN FibroGen	$0.75	-$4.00	-$4.75	$0.05	$2.00 million	$2.70 million
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/6/2025	Q1 2025	DVAX Dynavax Technologies	$0.03	-$0.11	-$0.14	-$0.77	$70.01 million	$68.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
FGEN FibroGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
BHVN Biohaven	N/A	2.33	2.33
DVAX Dynavax Technologies	0.49	11.93	10.84
FGEN FibroGen	N/A	2.02	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
BHVN Biohaven	88.78%
DVAX Dynavax Technologies	96.96%
FGEN FibroGen	72.71%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
BHVN Biohaven	14.60%
DVAX Dynavax Technologies	2.98%
FGEN FibroGen	1.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
DVAX Dynavax Technologies	350	120.08 million	116.50 million	Optionable
FGEN FibroGen	570	4.04 million	3.96 million	Optionable

FGEN, BHVN, AMLX, and DVAX Headlines

Recent News About These Companies

FibroGen (NASDAQ:FGEN) Raised to "Hold" at Wall Street Zen

June 22 at 2:01 AM | americanbankingnews.com

FibroGen (NASDAQ:FGEN) Trading Down 6.7% - What's Next?

June 17, 2025 | marketbeat.com

FibroGen To Implement 1-for-25 Reverse Stock Split

June 14, 2025 | nasdaq.com

FibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025

June 14, 2025 | nasdaq.com

FibroGen Enters Relicensing Agreement with HiFiBiO

June 14, 2025 | marketwatch.com

FibroGen Announces 1-for-25 Reverse Stock Split

June 12, 2025 | globenewswire.com

FibroGen, Inc. Appoints Dr. Michael Kauffman to Board of Directors

June 9, 2025 | quiverquant.com

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

June 9, 2025 | globenewswire.com

FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline

May 13, 2025 | msn.com

FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript

May 13, 2025 | msn.com

FibroGen, Inc.: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025 | finanznachrichten.de

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

A Preview Of FibroGen's Earnings

May 10, 2025 | benzinga.com

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 8, 2025 | globenewswire.com

FibroGen, Inc. to Announce Q1 2025 Financial Results and Host Conference Call on May 12

May 7, 2025 | nasdaq.com

FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

William Blair Keeps Their Hold Rating on FibroGen (FGEN)

April 2, 2025 | markets.businessinsider.com

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | globenewswire.com

FibroGen extends merger option deadline with Fortis

March 30, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FGEN, BHVN, AMLX, and DVAX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$5.02 -0.03 (-0.59%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$5.04 +0.02 (+0.30%)

As of 06/23/2025 07:50 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Biohaven NYSE:BHVN

$14.44 -0.03 (-0.17%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$14.42 -0.02 (-0.10%)

As of 06/23/2025 07:56 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Dynavax Technologies NASDAQ:DVAX

$9.77 -0.22 (-2.20%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$9.77 0.00 (0.00%)

As of 06/23/2025 07:08 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

FibroGen NASDAQ:FGEN

$5.40 -0.35 (-6.09%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$5.36 -0.04 (-0.83%)

As of 06/23/2025 05:56 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time